219 related articles for article (PubMed ID: 34958988)
1. Serum Prolactin Level to Tumor Size Ratio as a Potential Parameter for Preoperative Differentiation of Prolactinomas from Hyperprolactinemia-Causing Non-functional Pituitary Adenomas.
Kim JH; Hur KY; Hong SD; Choi JW; Seol HJ; Nam DH; Lee JI; Kong DS
World Neurosurg; 2022 Mar; 159():e488-e496. PubMed ID: 34958988
[TBL] [Abstract][Full Text] [Related]
2. Tumor volume improves preoperative differentiation of prolactinomas and nonfunctioning pituitary adenomas.
Wright K; Lee M; Escobar N; Pacione D; Young M; Fatterpekar G; Agrawal N
Endocrine; 2021 Oct; 74(1):138-145. PubMed ID: 33966173
[TBL] [Abstract][Full Text] [Related]
3. Role of prolactin/adenoma maximum diameter and prolactin/adenoma volume in the differential diagnosis of prolactinomas and other types of pituitary adenomas.
Huang Y; Ding C; Zhang F; Xiao D; Zhao L; Wang S
Oncol Lett; 2018 Feb; 15(2):2010-2016. PubMed ID: 29399201
[TBL] [Abstract][Full Text] [Related]
4. The value of prolactin in predicting prolactinοma in hyperprolactinaemic polycystic ovarian syndrome.
Kyritsi EM; Dimitriadis GK; Angelousi A; Mehta H; Shad A; Mytilinaiou M; Kaltsas G; Randeva HS
Eur J Clin Invest; 2018 Jul; 48(7):e12961. PubMed ID: 29845629
[TBL] [Abstract][Full Text] [Related]
5. Update on prolactinomas. Part 1: Clinical manifestations and diagnostic challenges.
Wong A; Eloy JA; Couldwell WT; Liu JK
J Clin Neurosci; 2015 Oct; 22(10):1562-7. PubMed ID: 26256063
[TBL] [Abstract][Full Text] [Related]
6. The outcome of hypophysectomy for prolactinomas in the era of dopamine agonist therapy.
Soule SG; Farhi J; Conway GS; Jacobs HS; Powell M
Clin Endocrinol (Oxf); 1996 Jun; 44(6):711-6. PubMed ID: 8759184
[TBL] [Abstract][Full Text] [Related]
7. Hyperprolactinemia and prolactinoma.
Romijn JA
Handb Clin Neurol; 2014; 124():185-95. PubMed ID: 25248588
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of transsphenoidal surgery in dopamine agonist-resistant prolactinomas: a retrospective study.
Wei L; Wei X
Hormones (Athens); 2021 Dec; 20(4):745-752. PubMed ID: 34275094
[TBL] [Abstract][Full Text] [Related]
9. Controversial issues in the management of hyperprolactinemia and prolactinomas - An overview by the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism.
Vilar L; Abucham J; Albuquerque JL; Araujo LA; Azevedo MF; Boguszewski CL; Casulari LA; Cunha Neto MBC; Czepielewski MA; Duarte FHG; Faria MDS; Gadelha MR; Garmes HM; Glezer A; Gurgel MH; Jallad RS; Martins M; Miranda PAC; Montenegro RM; Musolino NRC; Naves LA; Ribeiro-Oliveira Júnior A; Silva CMS; Viecceli C; Bronstein MD
Arch Endocrinol Metab; 2018; 62(2):236-263. PubMed ID: 29768629
[TBL] [Abstract][Full Text] [Related]
10. [Current diagnosis and treatment of hyperprolactinemia].
Melgar V; Espinosa E; Sosa E; Rangel MJ; Cuenca D; Ramírez C; Mercado M
Rev Med Inst Mex Seguro Soc; 2016; 54(1):111-21. PubMed ID: 26820213
[TBL] [Abstract][Full Text] [Related]
11. Hyperprolactinemia after menopause: Diagnosis and management.
Auriemma RS; Pirchio R; Pivonello R; Colao A
Maturitas; 2021 Sep; 151():36-40. PubMed ID: 34446277
[TBL] [Abstract][Full Text] [Related]
12. Diagnosis, treatment, and outcome of pituitary tumors and other abnormal intrasellar masses. Retrospective analysis of 353 patients.
Gsponer J; De Tribolet N; Déruaz JP; Janzer R; Uské A; Mirimanoff RO; Reymond MJ; Rey F; Temler E; Gaillard RC; Gomez F
Medicine (Baltimore); 1999 Jul; 78(4):236-69. PubMed ID: 10424206
[TBL] [Abstract][Full Text] [Related]
13. GIANT PROLACTINOMA. A CASE REPORT.
Šulavíková Z; Krásnik V
Cesk Slov Oftalmol; 2023; 79(3):143-148. PubMed ID: 37344216
[TBL] [Abstract][Full Text] [Related]
14. What is the optimal prolactin cutoff for predicting the presence of a pituitary adenoma in patients with polycystic ovary syndrome?
Kim SI; Yoon JH; Park DC; Yang SH; Kim YI
Int J Med Sci; 2023; 20(4):463-467. PubMed ID: 37057215
[No Abstract] [Full Text] [Related]
15. The Prolactin per Unit Tumor Volume Ratio Accurately Distinguishes Prolactinomas From Secondary Hyperprolactinemia due to Stalk Effect.
Faje A; Jones P; Swearingen B; Tritos NA
Endocr Pract; 2022 Jun; 28(6):572-577. PubMed ID: 35339688
[TBL] [Abstract][Full Text] [Related]
16. Prolactinomas and nonfunctioning adenomas: preoperative diagnosis of tumor type using serum prolactin and tumor size.
Burke WT; Penn DL; Castlen JP; Donoho DA; Repetti CS; Iuliano S; Barkhoudarian G; Laws ER
J Neurosurg; 2019 Jun; 133(2):321-328. PubMed ID: 31200381
[TBL] [Abstract][Full Text] [Related]
17. Falsely low serum prolactin in two cases of invasive macroprolactinoma.
Schöfl C; Schöfl-Siegert B; Karstens JH; Bremer M; Lenarz T; Cuarezma JS; Samii M; von zur Mühlen A; Brabant G
Pituitary; 2002; 5(4):261-5. PubMed ID: 14558675
[TBL] [Abstract][Full Text] [Related]
18. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
Colao A; Ferone D; Lastoria S; Cerbone G; Di Sarno A; Di Somma C; Lucci R; Lombardi G
Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic criteria of small sellar lesions with hyperprolactinemia: Prolactinoma or else.
Cho A; Vila G; Marik W; Klotz S; Wolfsberger S; Micko A
Front Endocrinol (Lausanne); 2022; 13():901385. PubMed ID: 36147567
[TBL] [Abstract][Full Text] [Related]
20. Diagnosis and management of hyperprolactinemia: results of a Brazilian multicenter study with 1234 patients.
Vilar L; Freitas MC; Naves LA; Casulari LA; Azevedo M; Montenegro R; Barros AI; Faria M; Nascimento GC; Lima JG; Nóbrega LH; Cruz TP; Mota A; Ramos A; Violante A; Lamounier Filho A; Gadelha MR; Czepielewski MA; Glezer A; Bronstein MD
J Endocrinol Invest; 2008 May; 31(5):436-44. PubMed ID: 18560262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
